All the news Showing 10 of 56 articles from: Genotype 1bGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Sofosbuvir/ledipasvir is safe and effective for relapsers and hard-to-treat patients Liz Highleyman / 11 April 2014 A co-formulation of sofosbuvir and ledipasvir successfully treated a variety of difficult-to-treat patient populations including people with hepatitis C virus (HCV) genotype 3, people with decompensated cirrhosis and people who were not cured ... Sofosbuvir/ledipasvir produces early cure for 100% of people with HIV and HCV co-infection Liz Highleyman / 11 April 2014 Treatment for 12 weeks with a co-formulation of sofosbuvir and ledipasvir led to sustained response for all participants with HIV and HCV co-infection who had genotype 1 hepatitis C virus ... AbbVie interferon-free regimen cures 96% of treatment-experienced genotype 1 hepatitis C infections Keith Alcorn / 11 April 2014 A 12-week course of three direct-acting antivirals developed by AbbVie, plus ribavirin, cured 96.3% of treatment-experienced patients with hepatitis C genotype 1 infection, Professor Stefan Zeuzem of the JW Goethe University Hospital, Frankfurt, ... Interferon-free BMS combo cures 90% of genotype 1 hepatitis C Liz Highleyman / 27 March 2014 An all-oral regimen of daclatasvir, asunaprevir and BMS-791325 – without interferon or ribavirin – led to sustained response in approximately 90% of people with hepatitis C virus (HCV) who had not previously ... Daclatasvir plus simeprevir are effective against hepatitis C genotype 1b Liz Highleyman / 25 March 2014 An all-oral regimen of daclatasvir plus simeprevir, without interferon or ribavirin, led to sustained response in 85 to 95% of people with hepatitis C genotype 1b, but this combination did not work ... Merck combination suppresses HCV in mono-infected and co-infected patients Liz Highleyman / 25 March 2014 An all-oral combination of the hepatitis C virus (HCV) protease inhibitor MK-5172 and NS5A inhibitor MK-8742, with or without ribavirin, demonstrated promising end-of-treatment viral suppression in people with HIV and HCV co-infection and ... Sofosbuvir & ribavirin cures 75% of genotype 1 HIV/HCV co-infected patients Liz Highleyman / 17 March 2014 An interferon-free regimen of sofosbuvir plus ribavirin for 24 weeks led to sustained response in three-quarters of previously untreated people with genotype 1 hepatitis C and HIV co-infection in the PHOTON-1 study, and in ... AbbVie '3D' combination cures 99% of genotype 1b hepatitis C Keith Alcorn / 14 March 2014 A 12-week triple combination of direct-acting antivirals developed by AbbVie cured at least 99% of previously untreated people with genotype 1b hepatitis C infection, Prof. Rajendar Reddy of the University of Pennsylvania Hospital ... US medical societies launch new hepatitis C treatment guidelines Liz Highleyman / 30 January 2014 The American Association for the Study of Liver Diseases (AASLD), Infectious Diseases Society of America (IDSA) and International Antiviral Society-USA (IAS-USA) yesterday announced the first new hepatitis C treatment guidelines ... Daclatasvir + sofosbuvir shows high hep C cure rate, new studies underway Liz Highleyman / 22 January 2014 A dual oral regimen of daclatasvir plus sofosbuvir cured more than 90% of chronic hepatitis C patients without interferon or ribavirin, according to a report in the January 16, 2014, New England Journal of ... ← Prev12345...6Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive